Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06290622
Status:
WITHDRAWN
Last Update Posted:
2024-06-28
First Post:
2024-02-26
Brief Title:
PD-1 LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
Sponsor:
University of Alabama at Birmingham
Organization:
University of Alabama at Birmingham
Study Overview
Official Title:
PD-1 LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre PLATEAU Study
Status:
WITHDRAWN
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Investigator request to no longer pursue this study Lack of support from drug company This trial never opened Withdrew IND
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy Additionally the study will investigate that triple checkpoint blockade of PD-1 TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None